The Peptide Report
A generation of high-performing executives has quietly traded IV drips and pills for a faster-absorbing NAD+ nasal spray. Here's why the format change matters — and what the science says.
Inside the quiet shift among finance, law, and tech leaders away from caffeine and toward intranasal NAD+. A look at the cellular science driving the new executive performance playbook.
The afternoon crash isn't a willpower problem—it's a cellular one. Here's why high performers are quietly trading their fourth coffee for a faster, cleaner alternative.
The afternoon crash isn't a willpower problem—it's a mitochondrial one. Here's why high-performers are quietly trading their 3 PM espresso for a faster, cleaner cellular reset.
